NovoCure Ltd — Director's Dealing 2021

May 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-05-10

Reporting Person: Benaim Ely (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-10	Ordinary Shares	M	1833	$47.56	Acquired	35092	Direct
2021-05-10	Ordinary Shares	S	1833	$189.65	Disposed	33259	Direct
2021-05-11	Ordinary Shares	S	2262	$180.118	Disposed	30997	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-10	Options to Buy Ordinary Shares	$47.56	M	1833	Disposed	2029-05-07	Ordinary Shares (1833.0)	Direct

Footnotes

F1: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.

F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3: Fully vested as of the date hereof.